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Abstract
Background: Hedonic hunger refers to consumption of food just for pleasure and not to maintain energy
homeostasis. Recently, consumption of food for pleasure was reported to be associated with increased
circulating levels of both the orexigenic peptide ghrelin and the endocannabinoid 2-arachidonoyl-glycerol (2-
AG) in normal-weight subjects. To date, the effects of hedonic hunger, and in particular of chocolate craving,
on these mediators in obese subjects are still unknown.
Methods: To explore the role of some gastrointestinal orexigenic and anorexigenic peptides and endocannabinoids
(and some related congeners) in chocolate consumption, we measured changes in circulating levels of ghrelin,
glucagon-like peptide 1 (GLP-1), peptide YY (PYY), anandamide (AEA), 2-AG, palmitoylethanolamide (PEA),
and oleoylethanolamide (OEA) in 10 satiated severely obese subjects after consumption of chocolate and, on
a separate day, of a non-palatable isocaloric food with the same bromatologic composition. Evaluation of
hunger and satiety was also performed by visual analogic scale.
Results: The anticipatory phase and the consumption of food for pleasure were associated with increased
circulating levels of ghrelin, AEA, 2-AG, and OEA. In contrast, the levels of GLP-1, PYY, and PEA did not
differ before and after the exposure/ingestion of either chocolate or non-palatable foods. Hunger and satiety
were higher and lower, respectively, in the hedonic session than in the non-palatable one.
Conclusions: When motivation to eat is generated by exposure to, and consumption of, chocolate a peripheral
activation of specific endogenous rewarding chemical signals, including ghrelin, AEA, and 2-AG, is observed
in obese subjects. Although preliminary, these findings predict the effectiveness of ghrelin and endocanna-
binoid antagonists in the treatment of obesity.
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ating may be pleasurable and rewarding. In fact,
food intake is motivated not only by the need to
restore energy homeostasis; palatable, rewarding
high-fat and/or sugar foods such as chocolate can moti-
vate eating despite a state of satiety and positive energy
balance. This phenomenon has been defined as ‘hedonic
hunger’ in contraposition with ‘homeostatic hunger’,
which is essentially triggered by energy deprivation (1).
Reportedly, obesity reflects an energy imbalance in
which genetically susceptible individuals become increas-
ingly vulnerable to an ‘obesogenic’ environment. Thus,
both the palatability and availability of foods in the
Western diet play a major role in the development of
this (dramatically widespread) disease (2). An emerging
hypothesis concerns the role of the brain’s reward system
that responds to the stimulus provided by rewarding and
palatable ‘obesogenic’ foods and appears to override the
homeostatic signals for body weight control (3). Indeed,
mismatch between the hedonic value attributed to food
and energy needs is characteristic of eating disorders,
including (morbid) obesity. Therefore, understanding the
physiological and pathophysiological mechanisms under-
lying the hedonic hunger may help to counteract obesity.
Animal data support the view that distinguishable
although overlapping neural and peripheral pathways,
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involving several appetite-regulating substances, drive
homeostatic- and hedonic-based eating (4, 5). Importantly,
anticipatory effects to food are brain mediated, while
changes in peripheral hormones are a related consequence.
Several gastrointestinal endocrine cells produce and
secrete satiety hormones in response to food consumption
and digestion. These hormones, including cholecystokinin
(CCK), peptide YY (PYY), and glucagon-like peptide
1 (GLP-1), suppress homeostatic hunger and promote
satiation and satiety mainly through hindbrain circuits,
thus governing meal-by-meal eating behavior. Addition-
ally, the hypothalamus integrates adiposity signals, speci-
fically leptin, to regulate long-term energy balance and body
weight. Distinct hypothalamic areas and various orexigenic
and anorexigenic neurons have been identified to home-
ostatically regulate food intake. The hypothalamic circuits
regulate food intake in part by modulating the sensitivity
of the hindbrain to short-term satiety hormones (6).
In contrast, the hedonic and incentive properties of
foods and food-related cues are processed by the cortico-
limbic reward circuits. The mesolimbic dopamine sys-
tem encodes subjective ‘liking’ and ‘wanting’ of palatable
foods, which is subjected to modulation by the hindbrain
and the hypothalamic homeostatic circuits and by satiety
and adiposity hormones (6). A role for the orexigenic
stomach-derived peptide ghrelin in mediating reward
processes has also been demonstrated (7, 8). Particularly,
the ghrelin receptor, GHS-R1a, is expressed not only in
the hypothalamus but also in tegmental and mesolimbic
areas involved in reward, such as the ventro tegmental
area (VTA) and laterodorsal tegmental areas (LDTg);
furthermore, intra-VTA or intra-LDTg administration of
ghrelin increases accumbal dopamine release (7).
The endocannabinoids anandamide (AEA) and 2-
arachidonoyl-glycerol (2-AG) are two lipid mediators
that play a major role in the stimulation of food intake.
They exert this function by activating cannabinoid type 1
(CB1) receptors, which are widely distributed in several
brain areas, including those involved in the homeostatic
and hedonic control of feeding (9, 10). Under normal
physiological conditions in rodents, hypothalamic and
limbic forebrain endocannabinoids transiently increase
after food deprivation and decrease after food ingestion,
possibly due to stimulatory or inhibitory effects by hor-
mones whose circulating levels are modulated by food
deprivation, such as ghrelin and leptin. These changes
have been described to occur also in the human plasma (9).
Based on these considerations, one might hypothesize
that endocannabinoid and gastrointestinal (orexigenic
and anorexigenic) peptide responses to highly pleasurable
food should differ from those to non-palatable food, in
order to drive the motivation to eat even when there is no
negative energy imbalance and, thus, to promote adipose
tissue accumulation and obesity. Recently, Monteleone
et al. (11, 12) showed that, in normal-weight healthy
subjects, the consumption of food for pleasure was asso-
ciated with increased circulating levels of both ghrelin
and 2-AG, and that this response is disrupted in women
with anorexia nervosa. These intriguing results should
be confirmed and extended also to patients with obesity
to better understand, in a pathophysiological context,
the phenomenon of hedonic eating, which could power-
fully influence food intake and, ultimately, body mass.
In particular, chocolate consumption is a paradigm of
hedonic eating that is often used in animal models of
hyperphagia and obesity, but, as far as we know, its effect
on endocannabinoid levels in humans has not been
investigated. This is an important issue also in view of
previous reports that have discussed whether or not the
hedonic properties of chocolate can be ascribed in part
to the presence in this food of very low amounts of
endocannabinoids and related lipids (13, 14).
Thus, in order to explore the role of endocannabinoids
and gastrointestinal peptides, specifically, ghrelin, PYY,
and GLP-1, in hedonic eating in the obese state, we have
measured here changes in the circulating levels of these
mediators before and after the consumption of chocolate
in satiated severely obese adults.
Materials and methods
Subjects
Ten male obese subjects, aged 1944 yr (mean9SD
33.999.0 yr), having a mean BMI9SD 42.693.5 kg/m2,
were enrolled into the study. The obese subjects were
recruited from the Division of Metabolic Diseases at
Istituto Auxologico Italiano, IRCCS, Verbania, Italy.
Each participant enrolled in the study was requested
to fulfil the following conditions:
1. to positively respond to the following question: Is
chocolate one of your most favorite foods that you
would eat also when satiated, just for pleasure? (This
is different from the protocol by Monteleone et al.
(12), where the question was: What is your most
favourite food that you would eat also when satiated,
just for pleasure?  where chocolate was not always
the answer.)
2. to give a palatability score ]8 for chocolate, being
the administered scale ranging from 0 (not-palata-
ble) to 10 (maximally palatable).
Exclusion criteria included previous diagnosis of any
disease affecting the endocrine system and metabolism
(apart from obesity), chronic use of medications affecting
metabolism and/or appetite, ]5.0 kg weight change during
the 3 months preceding study participation, allergies to
or stated dislike of the components of the test meal (see
below), and clinically diagnosed eating disorder or a
score of ]20 on the eating attitudes test (15). No subject
was a marijuana smoker, an alcohol consumer, or heavy
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cigarette smoker, which are conditions known to affect
circulating levels of endocannabinoids.
The experimental protocol was approved by the local
ethical committee and all subjects gave their written
consent after being fully informed of the nature and pro-
cedures of the study. Therefore, each subject was aware
that, in the first session of the experimental protocol, he
would have eaten chocolate.
Study design
The experiment used a within-subject repeated-measure
design in which each volunteer served as his own control,
similar to that used by Monteleone et al. (12). All subjects
were tested two times with an interval in-between the tests
of at least 7 days. A single-blind, Latin-square crossover
design could not be applied because of the experimental
needs of evoking the anticipatory effect of palatable
food and of administering a non-palatable food with the
same nutrients (isobromatologic) and calorie (isoenergetic)
amounts of the consumed palatable food (see below). The
anticipation to food intake consisted in two periods: 1)
when obese subjects were informed about the (palatable/
non-palatable) food they would have eaten (T0T60) and
2) when obese subjects could have sensorial experiences
related to the (palatable/non-palatable) food (T60T70).
On the first test session, participants arrived at our
Clinical Investigation Unit at 08:30 h after a 12-h fast.
At 09:00 h, they were asked to rate their hunger and
satiety on visual analog scales (VAS) that used a 10-cm
line with labels at the extremities indicating the most
negative and the most positive ratings; immediately after-
ward, an intravenous catheter was inserted into an
antecubital vein to collect a first blood sample (time
(T)0); the catheter was connected to a saline solution,
which was slowly infused to keep it patent through the
entire experimental session. Then, the subjects received
a breakfast of 300 kcal, with 77% carbohydrates, 10%
proteins, and 13% fats. Immediately after breakfast
(consumed within 10 min), they rated again their hunger
and satiety by means of VAS. Further blood samples were
drawn (T10 and T30 at 10 min and 30 min, respectively).
After 1 h from the start of the study, the subjects were
told that they would receive chocolate. Immediately
afterwards, each participant was exposed to the palatable
food for 10 min. During this time, he could smell and see
the food but could not eat it. At the end of the exposure,
each participant was asked to rate his hunger, satiety by
means of VAS. Blood samples were drawn at 60 min and
70 min (i.e. T60 and T70). Then, the subject was free
to eat the palatable food (see below for details) within
10 min. Additional blood samples were drawn immedi-
ately after the exposure to the palatable food (T80) and at
100 min (T100), 130 min (T130), 160 min (T160), and 190
min (T190); at the same time points, they rated again
their hunger and satiety by means of VAS.
At the end of the session, the amount of food eaten by
each participant was calculated by weighing the residual
food and subtracting it from the initial amount of food
provided, and then the calories eaten were calculated.
On the second test session, carried out at least 7 days
later, participants underwent the same experimental
procedures of the first experimental session except for
the fact that they were exposed to non-palatable food and
had to eat an amount of it with the same nutrient com-
position and an equal quantity of calories (i.e. isobro-
matologic and isoenergetic) as the palatable food they ate
in the previous session within 10 min.
During the food exposure (specifically, from T60 to
T70), a total of 20 pictures of chocolate-based foods and
of landscapes and nature were shown in the session with
chocolate and non-palatable foods, respectively.
Palatable and non-palatable foods
The palatable food was a milk-chocolate tablet (200 g for
a total of 1,000 kcal with 61.4% carbohydrates, 7.9%
proteins, and 30.7% fat), served in a dish from which the
subject was free to eat until he became satiated (for a
maximum corresponding to the whole chocolate tablet).
The non-palatable food, which was identified by all
participants as non-desirable just for pleasure (specifi-
cally, with a palatability score B2) consisted of bread
and butter, which were combined ad hoc to provide the
same nutrients (isobromatologic) and calorie (isoener-
getic) amounts of the consumed chocolate. Calorie and
nutrient contents of palatable and non-palatable foods
were calculated by using the information reported on the
labels of each packaged foods (chocolate tablet and
butter). To calculate calorie and nutrient content of bread,
we obtained the recipe from the baker who made it.
To maintain a stable daily caloric intake of the in-
hospital obese patients, the amount of foods adminis-
tered at lunch and dinner of the experimental days was
proportionally reduced to account for the calories of the
test meals (i.e. chocolate or non-palatable food).
Evaluation of body composition
Anthropometric characteristics were evaluated during the
screening period. BMI was calculated from measured
height and weight. Fat-free mass (FFM) and fat mass
(FM) were evaluated by the bioelectrical impedance
analysis (Human-IM Scan, DS-Medigroup, Milan, Italy).
Blood sampling and biochemical measurements
Blood was collected in tubes with or without antic-
oagulant (EDTA). Plasma or serum was separated by
centrifugation and stored at 208 C.
Total plasma ghrelin level, including both octanoylated
and des-octanoylated ghrelin, was measured by a com-
mercially available RIA for ghrelin (Millipore, Saint
Charles, MO). The sensitivity of the method was 93 pg/ml;
Hedonic feeding in obesity
Citation: Food & Nutrition Research 2015, 59: 29678 - http://dx.doi.org/10.3402/fnr.v59.29678 3
(page number not for citation purpose)
intra- and interassay coefficients of variation (CVs) were
10.0 and 14.7%, respectively.
Total plasma PYY level, including both PYY1-36 and
PYY3-36, was measured by a commercially available
RIA for PYY (Millipore). The sensitivity of the method
was 10 pg/ml; intra- and interassay CVs were 2.9 and
7.1%, respectively.
Total plasma GLP-1 level, including GLP-17-36 amide,
GLP-17-37, GLP-19-36 amide, GLP-19-37, GLP-11-36
amide, and GLP-11-37, was measured, after an extrac-
tion procedure, by RIA (Millipore). A DPP-4 inhibitor
was added to tubes to prevent the breakdown of GLP-1.
The sensitivity of the method was 3 pmol/l; intra- and
interassay CVs were 2.9 and 7.1%, respectively.
Serum insulin concentration was determined by che-
miluminescent immunometric assay using a commercial
kit (Immulite 2000, DPC, Los Angeles, CA). The sen-
sitivity of the method was 2 mIU/ml; intra- and interassay
CVs were 2238 and 1423%, respectively.
Serum glucose level was measured by the glucose
oxidase enzymatic method (Roche Diagnostics, Monza,
Italy).
Plasma levels of AEA, 2-AG, oleoylethanolamide
(OEA), and palmitoylethanolamide (PEA) were deter-
mined by isotopic dilution-liquid chromatographymass
spectrometry as described previously (15, 16).
Statistical analysis
The Sigma Stat 3.5 statistical software package was used
for data analysis. GraphPad Prisma 5.0 software was
used for plotting data. The ShapiroWilk test showed
that all parameters were normally distributed.
Results are reported as mean9SD (standard devia-
tion). The responses in glucose, insulin, ghrelin, PYY,
GLP1, AEA, 2-AG, PEA, OEA, and VAS scores for
hunger and satiety were evaluated as absolute values and
also as area under the curve (AUC) of postprandial mea-
surements using the trapezoid rule for each experimental
session of eating (breakfastchocolate and breakfast
non-palatable with AUC0190 for ghrelin, GLP-1, PYY,
VAS scores for hunger and satiety, glucose and insulin,
and AUC60190 for AEA, 2-AG, PEA, and OEA).
All parameters (ghrelin, PYY, GLP-1, VAS scores for
hunger and satiety, glucose and insulin) were compared
within each experimental session of eating (breakfast
chocolate and breakfastnon-palatable food) over sam-
pling times (intra-group analysis) and between the two
experimental sessions of eating for any sampling time
(inter-group analysis) by using a two-way ANOVA with
repeated measures (with the two factors: time and session
and the interaction timesession), followed by the post-
hoc Tukey’s test, which was used to compare responses
after breakfast (i.e. T10, T30, and T60 vs. 0 min) and
the responses after chocolate or non-palatable food (i.e.
T80, T100, T130, T160, and T190 vs. 70 min) for both
experimental sessions of eating (i.e. breakfastchocolate
and breakfastnon-palatable food). The same statistical
test was applied for analyzing the responses in endocan-
nabinoids (AEA, 2-AG, PEA, and OEA) only after the
second part of the experimental session (i.e. T70, T100,
T130, and T190 vs. 60 min for both experimental sessions
of eating). Student’s t-test was used to compare AUCs of
each peptide or endocannabinoids in both experimental
sessions. Pearson’s product-moment correlation test (for
all data) was employed to analyze possible correlations
among the variables. A level of significance of pB0.05
was used for all data analyses.
Results
Body composition and other clinical information
The percent FM was 41.295.1%, and the percent FFM
was 58.995.1% (Table 1).
No statistically significant differences in body weight were
found in all obese subjects between the first (breakfast
chocolate) and second (breakfastnon-palatable food)
sessions of eating (data not shown).
Calorie ingestion
No statistically significant difference emerged in the mean
values of calories and nutrients of palatable and non-
palatable foods (data not shown), confirming the preci-
sion of dietetic calculations (see above). Obese subjects
ate 152.4948.5 g of chocolate (range: 74200 g), which
corresponds to 787.19230.6 kcal (range: 3961,000 kcal).
Circulating levels of gastrointestinal peptides: ghrelin, PYY,
and GLP-1
Ghrelin
The timesession repeated-measures ANOVA yielded
significant main effects for time (F(9)4.36, pB0.01)
and session (F(1)19.41, pB0.05), without any signifi-
cant interaction for timesession (F(9)1.65), indicat-
ing that circulating levels of ghrelin changed significantly
over sampling times and between the experimental ses-
sions of eating (i.e. administration of breakfastchocolate
Table 1. Demographic and clinical characteristics of the obese
subjects enrolled in the study.
Obese subjects
Number (no.) 10
Age (yr) 33.499.0
BMI (kg/m2) 42.993.5
FFM (kg) 78.9912.6
FFM (%) 58.995.1
FM (kg) 54.897.8
FM (%) 41.295.1
BMIbody mass index; FMfree fat mass; FMfat mass.
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vs. breakfastnon-palatable food). Indeed, the post-hoc
Tukey’s test indicated that 1) there was a statistically sig-
nificant decrease in circulating levels of ghrelin at 60 min
(vs. 0 min after the breakfast, pB0.01) in obese patients
administered with the breakfastchocolate session,
without any difference in those administered with the
breakfastnon-palatable session (intra-group analysis)
and 2) the obese subjects tested with the hedonic session,
when compared with the non-palatable session, had
significantly higher plasma concentrations of ghrelin at
all times (pB0.01), except for 160 min and 190 min
(inter-group analysis) (Fig. 1).
PYY
The timesession repeated-measures ANOVA yielded a
significant main effect for time (F(9)2.04, pB0.01),
without any significant effect for session (F(1)0.05) and
interaction for timesession (F(9)0.53), indicating
that circulating levels of PYY changed significantly over
the sampling times, but not between the two experimental
sessions of eating. Indeed, the post-hoc Tukey’s test
indicated that administration of both experimental ses-
sions of eating (i.e. breakfastchocolate or breakfast
non-palatable food) evoked an identical statistically sig-
nificant increase in circulating levels of PYY at 130 min,
160 min, and 190 min (vs. 70 min after hedonic or non-
palatable food, pB0.01) (intra-group analysis) (Fig. 1).
GLP-1
The timesession repeated-measures ANOVA yielded no
significant main effects for time (F(9)0.40) and session
(F(1)0.64) and no significant interaction for time
session (F(9)1.67), indicating that circulating levels
of GLP-1 did not change significantly over sampling
times and between the two experimental sessions of
eating (Fig. 1).
Circulating levels of endocannabinoids and related
mediators: AEA, 2-AG, PEA, and OEA
AEA
The timesession repeated-measures ANOVA yielded
significant main effects for time (F(4)4.19, pB0.01)
and session (F(1)7.42, pB0.05), without any signifi-
cant interaction for timesession (F(4)0.21), indicat-
ing that circulating levels of AEA changed significantly
over sampling times and between the experimental ses-
sions of eating (i.e. administration of breakfastchocolate
vs. breakfastnon-palatable food). Indeed, the post-hoc
Tukey’s test indicated that 1) there was a statistically
significant decrease in circulating levels of AEA at 190
min (vs. 60 min, pB0.05) in obese patients administered
with the breakfastchocolate session, without any dif-
ference in those administered with the breakfastnon-
palatable-food session (intra-group analysis) and 2) the
obese subjects tested with the hedonic session, when com-
pared with the non-palatable session, had significantly
GLP-1
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Fig. 1. Changes of circulating levels of ghrelin (top panel),
GLP-1 (middle panel) and PYY (bottom panel) in obese
subjects after breakfast (at the left of the dotted vertical line, i.e.
T0T70) and chocolate or non-palatable meal (at the right of
the dotted vertical line, i.e. T70T190) during the hedonic and
non-palatable sessions of eating, respectively. Breakfast was
consumed from T0 to T10, while chocolate or non-palatable
meal was consumed from T70 to T80 after a sensorial exposure
of the foods and view of pictures of chocolate-based foods (in
the hedonic session) or landscapes and nature (in the non-
palatable session) from T60 to T70. See the text for further
details. Values are expressed as mean9SD. *pB0.05 vs. the
corresponding time point of the non-palatable session;
pB0.05 vs. the corresponding T0 or T70 value.
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higher plasma concentrations of AEA at 60 min
(pB0.05) (inter-group analysis) (Fig. 2).
2-AG
The timesession repeated-measures ANOVA yielded a
significant main effect for session (F(1)1.40, pB0.05),
without any significant main effect for time (F(4)0.11)
and interaction for timesession (F(4)3.00), indicat-
ing that circulating levels of 2-AG did not change sig-
nificantly over sampling times, but did between the experi-
mental sessions of eating. Indeed, the post-hoc Tukey’s
test indicated that 1) there was no statistically significant
difference in circulating levels of 2-AG in obese patients
administered with the breakfastchocolate or breakfast
non-palatable-food session (intra-group analysis) and
2) the obese subjects tested with the hedonic session,
when compared with the non-palatable session, had
significantly higher plasma concentrations of 2-AG at
60 min (pB0.05) (inter-group analysis) (Fig. 2).
PEA
The timesession repeated-measures ANOVA yielded
no significant main effects for time (F(4)0.11) and
session (F(1)1.33) and no significant interaction for
timesession (F(4)0.17), indicating that circulating
levels of this non-endocannabinoid AEA homolog did
not change significantly over sampling times and between
the experimental sessions of eating (Fig. 2).
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Fig. 2. Changes of circulating levels of anandamide (AEA, top left panel), 2-arachidonoyl-glycerol (2-AG, top right panel),
palmitoylethanolamide (PEA, bottom left panel), and oleoylethanolamide (OEA, bottom right panel) in satiated obese subjects
before (i.e. T60T70) and after (i.e. T60T190) chocolate or non-palatable meal during the hedonic and non-palatable sessions
of eating, respectively. Chocolate or non-palatable meal was consumed from T70 to T80 after a sensorial exposure of the foods
and view of pictures of chocolate-based foods (in the hedonic session) or landscapes and nature (in the non-palatable session)
from T60 to T70. See the text for further details. Values are expressed as mean9SD. *pB0.05 vs. the corresponding time point
of the non-palatable session; pB0.05 vs. the corresponding T60 value.
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OEA
The timesession repeated-measures ANOVA yielded
significant main effects for time (F(4)12.97, pB0.01)
and session (F(1)2.24, pB0.05), without any signifi-
cant interaction for timesession (F(4)1.18), indicat-
ing that circulating levels of this non-endocannabinoid
AEA homolog changed significantly over sampling times
and between the experimental sessions of eating. Indeed,
the post-hoc Tukey’s test indicated that 1) there was
a statistically significant decrease in circulating levels
of OEA at 130 min and 190 min (vs. 60 min, pB0.05)
in obese patients administered with the breakfast
chocolate session, without any difference in those admi-
nistered with the breakfastnon-palatable-food session
(intra-group analysis) and 2) the obese subjects tested
with the hedonic session, when compared with the non-
palatable session, had significantly higher plasma con-
centrations of OEA at 60 min and 70 min (pB0.05)
(inter-group analysis) (Fig. 2).
VAS scores: hunger and satiety
Hunger
The timesession repeated-measures ANOVA yielded a
significant main effect for time (F(9)15.92, pB0.01)
and interaction for timesession (F(9)2.98, pB0.01),
without any significant main effect for session (F(1)
0.58), indicating that hunger VAS score changed sig-
nificantly over sampling times and between the experi-
mental sessions of eating (i.e. administration of breakfast
chocolate vs. breakfastnon-palatable food). Indeed, the
post-hoc Tukey’s test indicated that 1) there was a
statistically significant decrease in hunger VAS scores at
10 min, 30 min, and 60 min (vs. 0 min after the breakfast,
pB0.01) for both experimental sessions and at 80 min
and 100 min (vs. 70 min after the chocolate or non-
palatable foods in obese patients administered with the
breakfastchocolate and the breakfastnon-palatable-
food sessions, respectively, and also at 130 min, 160 min,
and 190 min (vs. 70 min after chocolate) only in the
hedonic session (intra-group analysis) and 2) the obese
subjects tested with the hedonic session, when compared
with the non-palatable session, had significantly higher
values in hunger VAS score at 30 min and 70 min
(pB0.01) (inter-group analysis) (Fig. 3).
Satiety
The timesession repeated-measures ANOVA yielded
significant main effects for time (F(9)25.80, pB0.01)
and for session (F(1)1.42, pB0.01), without any inter-
action for timesession (F(9)0.58), indicating that
satiety VAS score changed significantly over sampling
times and between the experimental sessions of eating.
Indeed, the post-hoc Tukey’s test indicated that 1) there
was a statistically significant increase in satiety VAS
scores at 10 min, 30 min, and 60 min (vs. 0 min after the
breakfast, pB0.01) for the breakfastchocolate and
breakfastnon-palatable-food sessions and at 100 min
and 130 min (vs. 70 min after the chocolate or non-
palatable food) for both sessions and also at 160 min and
190 min (vs. 70 min after the chocolate) only for the
breakfastchocolate session (intra-group analysis); 2)
the obese subjects tested with the hedonic session, when
compared with the non-palatable session, had signifi-
cantly lower values in satiety VAS score at 70 min
(pB0.01) (inter-group analysis) (Fig. 3).
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Fig. 3. Changes of VAS ratings of hunger (top panel) and
satiety (bottom panel) in obese subjects after breakfast (at
the left of the dotted vertical line, i.e. T0T70) and chocolate
or non-palatable meal (at the right of the dotted vertical line,
i.e. T70T190) during the hedonic and non-palatable
sessions of eating, respectively. Breakfast was consumed
from T0 to T10, while chocolate or non-palatable meal was
consumed from T70 to T80 after a sensorial exposure of the
foods and view of pictures of chocolate-based foods (in the
hedonic session) or landscapes and nature (in the non-
palatable session) from T60 to T70. See the text for further
details. Values are expressed as mean9SD. *pB0.05 vs. the
corresponding time point of the non-palatable session;
pB0.05 vs. the corresponding T0 or T70 value.
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Metabolic parameters: glucose and insulin
Glucose
The timesession repeated-measures ANOVA yielded a
significant main effect for time (F(9)10.93, pB0.01),
without any significant effect for session (F(1)3.68)
and interaction for timesession (F(9)1.52), indicat-
ing that glucose concentrations changed significantly
over the sampling times, but not between the two experi-
mental sessions of eating (i.e. administration of breakfast
chocolate vs. breakfastnon-palatable food). Indeed, the
post-hoc Tukey’s test indicated that administration of both
experimental sessions of eating (i.e. breakfastchocolate
or breakfastnon-palatable foods) evoked an identical
statistically significant increase in glucose concentrations
at 30 min and 60 min (vs. 0 min after breakfast, pB0.01)
(intra-group analysis) (Fig. 4).
Insulin
The timesession repeated-measures ANOVA yielded a
significant main effect for time (F(9)7.42, pB0.01),
without any significant effect for session (F(1)0.13) and
interaction for timesession (F(9)1.11), indicating
that insulin concentrations changed significantly over
the sampling times, but not between the two experimental
sessions of eating. Indeed, the post-hoc Tukey’s test
indicated that administration of both experimental ses-
sions of eating (i.e. breakfastchocolate or breakfast
non-palatable foods) evoked an identical statistically
significant increase in insulin concentrations at 30 min
and 60 min (vs. 0 min after breakfast, pB0.01) (intra-
group analysis) (Fig. 4).
AUCs of circulating levels of peptides, endocannabinoids,
and related mediators, of metabolic parameters and of
VAS scores for hunger and satiety
The AUC of circulating levels of ghrelin was significantly
higher in obese subjects administered with the break-
fastchocolate session than with the breakfast
non-palatable-food session. No statistically significant
differences were found for AUCs of circulating levels of
GLP-1 and PYY. The AUC of circulating levels of AEA
was significantly higher in obese subjects administered
with the breakfastchocolate session than with the
breakfastnon-palatable-food session. No statistically
significant differences were found for AUCs of circulating
levels of 2-AG, PEA, and OEA. No statistically signifi-
cant differences were found for VAS scores of hunger
and satiety and concentrations of glucose and insulin
(Table 2).
Correlations
Among the most relevant correlations, the AUC of cir-
culating levels of ghrelin was correlated with that of
OEA (r0.46, pB0.05); that of GLP-1 with that of
2-AG (r0.45, pB0.05); and that of AEA with that
of PEA (r0.74, pB0.01). Interestingly, the AUC of
hunger VAS score was correlated with that of AEA
(r0.68, pB0.05) and that of PEA (r0.58, pB0.01).
Values of BMI were correlated with AUCs of circulating
levels of AEA (r0.60, pB0.01), 2-AG (r0.49,
pB0.05), and PEA (r0.55, pB0.05). Values of FM
(kg) were correlated with AUCs of circulating levels of
GLP-1 (r0.51, pB0.05), AEA (r0.41, pB0.05),
and PEA (r0.54, pB0.01), while those of FM (%)
with the AUC of PEA (r0.39, pB0.05).
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Fig. 4. Changes of circulating levels of glucose (top panel)
and insulin (bottom panel) in obese subjects after breakfast
(at the left of the dotted vertical line, i.e. T0T70) and
chocolate or non-palatable meal (at the right of the dotted
vertical line, i.e. T70T190) during the hedonic and non-
palatable sessions of eating, respectively. Breakfast was
consumed from T0 to T10, while chocolate or non-palatable
meal was consumed from T70 to T80 after a sensorial
exposure of the foods and view of pictures of chocolate-
based foods (in the hedonic session) or landscapes and
nature (in the non-palatable session) from T60 to T70.
See the text for further details. Values are expressed as
mean9SD. *pB0.05 vs. the corresponding time point of
the non-palatable session; pB0.05 vs. the corresponding
T0 or T70 value.
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Discussion
Monteleone et al. (12), while investigating the regulation
of circulating levels of ghrelin and endocannabinoids
after hedonic eating in satiated normal-weight subjects,
have recently shown that the consumption of food for
pleasure was associated with increased circulating levels
of both ghrelin and 2-AG. In contrast, plasma levels of
both AEA and of the two AEA metabolically related
lipids and agonists of peroxisome proliferator-activated
receptor a (PPAR-a), PEA and OEA progressively de-
creased after the ingestion of both palatable and (iso-
energetic and isobromatologic) non-pleasurable food.
In the present study, higher circulating levels of ghrelin
were persistently found in obese subjects during the entire
hedonic session (breakfastpalatable-food session), in
which, 1 h after a breakfast, a chocolate tablet was ini-
tially served for a complete sensorial experience and then
freely consumed; in contrast, a stable lower profile in
circulating levels of ghrelin was found during the break-
fastnon-palatable-food session, in which the chocolate
was substituted for an isoenergetic and isobromatologic
non-palatable meal (bread and butter). In addition,
during the (first part of the) hedonic session, a significant
inhibition of ghrelin secretion occurred after breakfast,
which was unable to reduce circulating levels of the
same orexigenic peptide when obese subjects were being
included in the non-palatable session. Finally, the experi-
ence with the palatable food (i.e. the second part of the
session with the direct exposure to chocolate, view of
pictures of chocolate-based foods and consumption of
the chocolate tablet) significantly further increased ghre-
lin secretion, whereas there were no changes in circulating
levels of this peptide during the last part of the non-
palatable session, in which the non-palatable meal was
served in conjunction with the view of pictures of
landscapes and nature and, entirely, consumed.
In our experimental protocol, satiation was obtained
by eating a breakfast of 300 kcal. Although this could
seem an energy amount not enough to completely sup-
press hunger in obese subjects fasted from 12 h, eating
such an amount of calories at breakfast is in line with
Italian feeding habits and, therefore, better represents the
natural morning feeding condition in our participants.
The unexpected breakfast-suppressible hyperghreline-
mia in our obese subjects, tested in the hedonic session
of eating, was already present at T0 before starting the
experiment. This is in contrast with the low circulating
levels and the lack of any post-meal suppression of
ghrelin in obesity as demonstrated by the obese subjects
tested with the non-palatable session of the present study
and many other works (17, 18).
In our obese subjects, the ghrelin increase observed in
plasma before starting the experiment and also at T100
after administration of the palatable meal likely reflects
the stimulation of ghrelin secretion occurring in the
cephalic phase (or, alternatively, the anticipatory phase)
of ingestion of highly palatable food, when any (lean or
obese) individual thinks, sees, and/or smells the food but
does not eat it yet (19). The anticipatory effect of highly
palatable food is, obviously, a crucial aspect of our ex-
perimental protocol: specifically, the participants in the
present study knew that they would have eaten the highly
pleasurable food in the first experimental session, because
of the need to balance the energy amounts and broma-
tologic composition of the non-palatable food to that of
the palatable one.
However, at the beginning of the hedonic session of
eating and after the exposure to the palatable food, such
ghrelin increases (at T0 and T100) were (relatively) more
pronounced in the obese subjects enrolled in the present
study when compared with those observed in the normal-
weight subjects included in the study by Monteleone
Table 2. Areas under the curve (AUC) of circulating levels of peptides, endocannabinoids, and metabolic parameters and of VAS scores for
hunger and satiety.
Palatable Not-palatable p
Ghrelin (pg/mlmin) 110488.299905.7 87651.198611.8 pB0.05
GLP-1 (pmol/lmin) 8619.99727.5 11929.391294.6 
PYY (pg/mlmin) 23449.691208.8 23142.592188.2 
AEA (pmol/mlmin) 535.09225.7 374.0973.1 pB0.05
2-AG (pmol/mlmin) 599.19211.8 468.29184.4 
PEA (pmol/mlmin) 6995.194806.0 5409.693001.2 
OEA (pmol/mlmin) 3458.791055.5 2905.89862.4 
Hunger VAS (mmmin) 2002.592118.0 1875.093064.3 
Satiety VAS (mmmin) 12612.593643.7 13616.092966.3 
Glucose (mg/dlmin) 16600.091408.7 15672.592061.4 
Insulin (mIU/mlmin) 8007.693732.5 7676.194072.7 
AUC0-190 for ghrelin. PYY, GLP-1, VAS scores for hunger and satiety, glucose, and insulin.
AUC60-190 for AEA, 2-AG, PEA, and OEA.
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et al. (12), in which a similar protocol was adopted. Based
on these findings, one might argue that obese subjects,
who, similarly to normal-weight subjects (12), were aware
that they would have eaten a palatable food in that day
before starting the experiment and, actually, had an in-
tense sensorial exposure to the palatable food (T60T70),
are more sensitive to any food-related cues than normal-
weight subjects, with the consequence of a (relatively)
more pronounced stimulation of ghrelin secretion. This
secretory pattern of ghrelin was not present in obese
subjects during the non-palatable session, in which the
profile of circulating levels of ghrelin remained depressed
over the entire duration of the protocol. As previously
mentioned, this latter secretory pattern of ghrelin is that
more known and commonly described in most works
dealing with the effects of food intake on circulating
levels of this peptide (17, 18), without differentiating
administration of palatable and non-palatable foods,
which, as demonstrated by the present study, is crucial
to induce hyperghrelinemia.
A functional magnetic resonance imaging (fMRI)
study (20) showed that intravenous ghrelin administra-
tion in normal-weight subjects increases the neural re-
sponse to food pictures in brain areas implicated in
reward processing and appetitive behaviour, such as the
amygdala, ventral striatum, anterior insula, and orbito-
frontal cortex (OFC). Moreover, experimental data
demonstrated that injection of ghrelin into the third
ventricle of mice significantly increases locomotor activ-
ity as well as extracellular dopamine levels in the nucleus
accumbens (7), a neurochemical system involved in
reward and motivated behavior as well as in mediating
the incentive salience of food (21). There is some evidence
that activation of these neuroanatomic areas may be
influenced by abnormal ghrelin levels associated with
genetic risk for obesity or obese weight status (22).
Following exogenous administration of PYY336 and
GLP-1736 amide, both independently and in combination,
in fasted normal-weight individuals, reductions were
observed in neural activity in the striatum, insula, and
OFC in response to palatable food images (23), suggest-
ing downstream inhibitory effects of these hormones on
the same regions stimulated by ghrelin. Therefore, obese
individuals, having lower circulating PYY and insensitiv-
ity to GLP-1 (24, 25), would have, at least theoretically,
an increased activity in the striatum, insula, and OFC
during exposure to food.
As expected, in the present study, circulating levels of
PYY and GLP-1 were low and only a slow progressive
increase in PYY secretion was found after the second
part of the two sessions of eating, without any difference
between consumptions of palatable and non-palatable
meals.
So, if ghrelin-induced activation of the mesolimbic
dopamine reward system increases the incentive value of
food and facilitates food-seeking behavior (7), on the
basis of our data in obese subjects, it can be tentatively
speculated that an increased secretion of ghrelin, which,
similarly to normal-weight subjects (12), precedes and
ensues the consumption of the palatable food, potently
activates central reward pathways, which, differently from
normal-weight subjects (23), are not inhibited (or are
only weakly) by PYY and GLP-1. Therefore, in obese
subjects, who usually have low (homeostatic and also pro-
tective) ghrelin levels (17, 18), when exposed to palatable
food, eating is promoted not only by the anticipatory
increase in ghrelin secretion, but also by the insufficient
anorexigenic responses of PYY and GLP-1. Despite no
need for calorie ingestion, obese subjects eat just for the
rewarding properties of the highly pleasurable food, with
no or insufficient anorexigenic brake.
This view is confirmed by other data of the present
study, that is, 1) the efficacy of breakfast to reduce and
increase, respectively, the hunger and the satiety in both
sessions of eating (i.e. breakfastpalatable-meal and
breakfastnon-palatable-meal), indicating the induction
of a similar state of satiation with no need for calorie
ingestion, irrespective from the palatability of the next
meal and 2), importantly, the ability of the palatable food
to reduce less and increase less, respectively, the hunger
and the satiety (at 70 min) in the hedonic session of eating
(i.e. breakfastpalatable-meal).
The present study suggests the importance of palatable-
food-related cues, mainly sensorial ones, to stimulate
food intake in obese subjects. This appears to be medi-
ated by ghrelin in lean and obese subjects, but actually
amplified in obesity, with potential long-term detrimental
effects in an environment offering unlimited amounts of
palatable food. Administration of ghrelin antagonists,
which has been considered by some authors as an inap-
propriate therapeutic intervention because of low ghrelin
levels present in obese subjects (26, 27), might represent,
in light of these preliminary results, a valid solution
to block the rewarding effects of the hyperghrelinemia
preceding any exposure to palatable food and ingestion
of excessive amounts of hypercaloric foods in conditions
of positive energy balance. The same result might be
obtained with psychotherapy, aimed to desensitize the
‘food-addicted’ subject from palatable-food-related cues.
Further studies are mandatory to investigate the ther-
apeutic potential of these interventions in obesity.
The findings of the present study also suggest an
involvement of the endocannabinoids AEA and 2-AG,
and of the non-endocannabinoid AEA congener OEA
(see also below), in the modulation of hedonic eating.
Specifically, in our obese subjects, circulating levels of
AEA, 2-AG, and OEA were significantly higher at
T60, before the exposure to chocolate, being OEA the
only endocannabinoid that was also higher at T70, after
exposure to chocolate tablet and view of pictures of
Antonello E. Rigamonti et al.
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chocolate-based foods, but just before the consumption
of this palatable food. Furthermore, the AUC of circulat-
ing levels of AEA was significantly higher in obese
subjects administered with chocolate than non-palatable
food. Finally, there was a significant decrease of circulat-
ing levels of AEA and OEA only at the end of the
breakfastchocolate session (i.e. at T190), without any
differences for the other endocannabinoids 2-AG and
PEA in the same session and for all endocannabinoids in
breakfastnonpalatable-food session.
These data suggest an activation of endogenous pro-
duction of AEA, 2-AG, and OEA before exposure to
chocolate, an effect which is similar to the anticipatory
increase in ghrelin levels in hedonic eating, as discussed
above. Combination of increases in ghrelin and endo-
cannabinoids (at least, the well-known rewarding CB1
agonists AEA and 2-AG) would promote the ‘wanting to
eat’ and also the ‘liking eating’ in a condition of no
energy deprivation (28). Accordingly, in the present study,
hunger VAS score was positively correlated with circulat-
ing levels of AEA (and PEA). A limit of this argumenta-
tion is the missing measurement of endocannabinoids
before T60.
Data in laboratory animals suggest that exposure to
foods with high salience and incentive properties stimu-
late an endocannabinoid tone to induce dopamine release
in the limbic area (9). This might, in turn, lead to both
increased motivation to consume palatable foods (also
when there is no need for calorie ingestion) (i.e. wanting
to eat) and heighten rewarding effects after the consump-
tion of such foods (i.e. liking eating). Therefore, the in-
creased plasma levels of AEA and 2-AG that we found in
obese subjects exposed to the palatable food might be the
result of spill-over from the brain areas in the reward
system. Alternatively, circulating levels of these endocan-
nabinoids might reflect spill-over from peripheral tissues,
such as the small intestine and/or adipose tissue, which,
like the brain, respond to food deprivation and refeeding
with changes in local endocannabinoid levels (2931).
The possibility of a brain-driven control of endocanna-
binoid production in peripheral tissues may not be ruled
out; thus, the anticipatory effects of a highly palatable
food, which are centrally mediated, might influence spill-
over of endocannabinoids at a peripheral level from the
small intestine or adipose tissue. Further studies are
mandatory to determine whether the increased circulat-
ing levels of endocannabinoids reflect changes in periph-
eral tissues or in brain areas directly involved in reward.
This might be important to characterize new pharmaco-
logic targets for obesity.
In the work by Monteleone et al. (12), conducted in
normal-weight subjects who underwent a protocol similar
to ours, a positive correlation was found between ghrelin
levels and those of 2-AG, both measured as AUC, sug-
gesting an interaction between ghrelin and the endocan-
nabinoid system. In accordance with some studies in
laboratory animals (3234), it has been proposed that the
role of peripheral ghrelin in the rewarding effects of
highly pleasurable food is mediated by an activation of
the endogenous production of endocannabinoids, parti-
cularly 2-AG, or vice versa.
As demonstrated by the present study, in obese sub-
jects there was no correlation between ghrelin and 2-AG
or the other well-known rewarding CB1 agonist AEA, but
between ghrelin and OEA. To date, little evidence for a
role for PPAR-a and the two PPAR-a ligands, OEA and
PEA, in the rewarding effect of food has been reported,
apart from a single study, which pointed to counter-
rewarding actions for these compounds (35). Therefore, it
is difficult to interpret this correlation as well as the
finding of higher circulating levels of OEA (but not PEA)
in obese subjects exposed to chocolate, when compared
to those in breakfastnon-palatable-food session. This is
in contrast with the study by Monteleone et al. (12), in
which, in normal-weight subjects, the levels of OEA and
PEA were similar in both groups with palatable and non-
palatable foods, suggesting a causative role of the obese
state for the unique secretory pattern of OEA in our
obese subjects. Further studies in animals are mandatory
to understand the physiological role and the pathophy-
siological implications of the PPAR-a agonists, including
the endogenous PEA and OEA, in food intake and,
generally, reward.
Monteleone et al. (12) found significant decreases in
AEA, 2-AG, PEA, and OEA after meal consumption,
irrespectively from the palatability of the food. Although
insulin has been reported to reduce circulating levels of
AEA and 2-AG in a way inversely related to anthropo-
metric and metabolic predictors of insulin resistance
and dyslipidemia, without any specific information for
PEA and OEA (36), in the present study, the finding of
unchanged circulating levels of 2-AG and PEA after
administration of palatable food and of all endocanna-
binoids after non-palatable food is possibly due to the
inability of insulin to inhibit the biosynthesis, or up-
regulation of the degradation, of these compounds in our
insulin-resistant obese subjects (36). This explanation
may be challenged by the decline of circulating levels of
AEA after ingestion of palatable food, which, however,
was very slow and possibly due to potential circadian
changes in the levels of this compound, previously de-
scribed in the rat brain (37). On the contrary, the excep-
tion of OEA, whose circulating levels decreased after
ingestion of chocolate (but not non-palatable food),
seems to confirm the unique secretory pattern of this
presumably not-rewarding endocannabinoid in obese
subjects exposed to palatable food.
Before closing, some important aspects should be
mentioned.
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Due to the experimental design adopted in the present
study (i.e. fixed order, with subjects knowing ahead what
was coming per session), we cannot exclude systematic
order effects. We chose this design based on the argument
of the experimental needs of evoking the anticipatory
effect of palatable food and of administering a non-
palatable isocaloric and with the same macronutrient
composition as the consumed palatable food (chocolate).
This conditioning paradigm cannot be accomplished by
adopting any alternative design with randomized order
(e.g. administration of fixed portions, so that palatable
and non-palatable foods could have been matched on
energy and macronutrient content beforehand).
We have compared above our results in obese sub-
jects with those obtained in normal-weight subjects by
Monteleone et al. (12). However, although these authors
used a similar protocol, they employed a different type of
hedonic food. In fact, the subjects recruited in the present
study were asked to eat chocolate as one of their favorite
foods, whereas in the previous study, normal-weight
subjects were asked to select their most favorite food,
which was not necessarily chocolate. The possibility that
the exclusive use of chocolate in this study may have been
a source of differences in the observed results should not
be underestimated for at least two reasons: 1) chocolate is
reported to contain centrally acting compounds, which, if
reaching the brain after consumption, might explain the
rewarding properties of this food together with its unique
sensory properties, and might also modify (i.e. repress or
stimulate) both central or peripheral endocannabinoid
biosynthesis; 2) chocolate, especially milk chocolate, has
been described to contain endocannabinoids, albeit in
trace levels, as well as compounds such as OEA (13, 14).
This latter fact, however, is unlikely to have affected the
measured plasma levels of AEA, 2-AG, and OEA, which
were found here to be higher only before (T70) and/or
immediately after (T70) the consumption of chocolate vs.
non-palatable food. Furthermore, very low amounts of
dietary endocannabinoids and acylethanolamides are
likely to be immediately degraded in the gastrointestinal
tract before being adsorbed. However, possible modula-
tory actions of cocoa psychoactive components, such as
caffeine, theobromine, and phenylethylamine, on the
biosynthesis of these lipid mediators may have affected
their measured amounts at later time points.
Finally, we enrolled only a limited number of obese
male subjects. Women are known to have more preference
to chocolate than men (e.g. 91% of women crave on
chocolate vs. 59% of men (38). Thus, we expect that obese
female subjects will have an exaggerate ghrelin response
to palatable food, specifically chocolate. Further studies
are mandatory to investigate this (potential) gender-
related difference and to confirm the preliminary results
obtained in the present study.
In conclusion, possibly similar to normal-weight sub-
jects (12), when motivation to eat is generated by the
availability of highly palatable food and not just by food
deprivation, a peripheral activation of specific endogen-
ous rewarding chemical signals, including ghrelin, AEA,
and 2-AG, is observed in obese subjects. However, when
compared to that in normal-weight subjects, this response
seems to be amplified, especially for what concerns
ghrelin, with no anorexigenic post-meal responses in
GLP-1 and PYY. After the early withdrawal of rimona-
bant, a CB1 inverse agonist originally used to decrease
body weight in obesity, from the pharmaceutical market
because of safety concerns, the present preliminary study
may predict the effectiveness of ghrelin receptor and CB1
neutral antagonists in the treatment of hyperphagia and
bingeing on highly palatable foods in obesity.
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